Loading...
Please wait, while we are loading the content...
Similar Documents
Antiparasitical chemotherapy in Chagas’ disease cardiomyopathy: current evidence
| Content Provider | Scilit |
|---|---|
| Author | Guedes, Paulo Marcos Matta Gutierrez, Fredy Rs Nascimento, Manuela Do-Valle-Matta, Maria Adelaide Silva, Joao Santana |
| Copyright Year | 2012 |
| Description | Journal: Tropical Medicine & International Health Chronic chagasic cardiomyopathy affects 20% of Chagas disease patients. At present, Chagas disease chemotherapy uses nitrofurans, benznidazole (Rochagan (R), Rodanil (R), Roche) or nifurtimox (Lampit (R), Bayer). Treatment during acute and recent chronic phases in childhood effects 71.5% and 57.6%, respectively, of parasitological cure. However, in clinical trials during the late chronic phase, only 5.9% of parasitological cure were achieved. This review focuses on the benefit from aetiological treatment to avoid, stop or revert myocarditis. Divergent data gathered from clinical practice are not convincing to support prescription of aetiological treatment as routine for indeterminate and cardiac chronic patients |
| Ending Page | 1065 |
| Starting Page | 1057 |
| ISSN | 2573508X |
| e-ISSN | 13653156 |
| DOI | 10.1111/j.1365-3156.2012.03025.x |
| Journal | Tropical Medicine & International Health |
| Issue Number | 9 |
| Volume Number | 17 |
| Language | English |
| Publisher | Wiley-Blackwell |
| Publisher Date | 2012-06-12 |
| Access Restriction | Open |
| Subject Keyword | Journal: Tropical Medicine & International Health Trypanosoma Cruzi Parasite Persistence Cardiac Inflammation Maladie De Chagas Persistance Du Parasite Inflammation Cardiaque Enfermedad De Chagas Persistencia Parasitológica Inflamación Cardiaca |
| Content Type | Text |
| Resource Type | Article |